About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

0.7962 +0.0462 (+6.16%)
Delayed Quote Updated: 11:35 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session ↗
Via Chartmill
News headline image
Coherus Oncology Reports 89% Response Rate in Early ESCC Study ↗
Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The... 
Via MarketBeat
News headline image
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
Coherus Oncology (NASDAQ:CHRS) Q1 Revenue Misses Estimates Despite LOQTORZI Growth ↗
Via Chartmill
Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Grow ↗
Via Chartmill
News headline image
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript ↗
LOQTORZI sales surged 37% year-over-year as clinical programs advance toward key data readouts. 
Via The Motley Fool
Topics Earnings
News headline image
Coherus Oncology Q2 Earnings Call Highlights ↗
Coherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating... 
Via MarketBeat
Topics Earnings
News headline image
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Coherus Oncology Q1 Earnings Call Highlights ↗
Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data... 
Via MarketBeat
Topics Earnings
News headline image
CHRS Q1 2026 Earnings Transcript ↗
CHRS Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.